An observational study in Liver Cancer, Liver Metastases and Liver Metastasis Colon Cancer, sponsored by Leiden University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years to 110 Years. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Leiden University Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Carcinoma, Hepatocellular with a site in Netherlands — 19 open to participants now, 23 under way, 4 of them phase 3. Carcinoma, Hepatocellular · Netherlands.
Among the 53 studies in Carcinoma, Hepatocellular with a site in Netherlands, this one is the 7th largest by planned enrollment of the 13 observational ones that give a count, is one of 3 that started in 2024, is one of 13 observational ones, reaches primary completion later than 12 of the 22 other live ones, and was the 43rd registered.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
Browse Carcinoma, Hepatocellular studies →19 of the 53 studies in Carcinoma, Hepatocellular with a site in Netherlands are open now. Recruiting first, the newest first:
Mark C Burgmans, MD PhD · Sites in Netherlands, France
Ages 18+
Niek Wijnen · Sites in Netherlands
Ages 18+
Philipp Dutkowski · Sites in Netherlands, United States, Austria and 14 more countries
Ages 18+
AstraZeneca · Sites in Netherlands, United States, Australia and 17 more countries
Ages 18+
Maastricht University · Sites in Netherlands, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 743 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 253 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 110 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 10 · Phase 3 12 · Phase 4 1
First in 2008; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,500 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Median enrollment 156 across the 40 interventional studies, 1,500 across the 13 observational. Of the 28 that completed or were terminated, 11 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 53 have an industry lead sponsor. The 10 most frequent:
Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.
Leiden University Medical Center has 2 studies filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
4 of the studies in Carcinoma, Hepatocellular with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03017326Phase 3University of BirminghamPaediatric Hepatic International Tumour Trial | 2026-12-31 |
| NCT06518434University Medical Center GroningenA Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients | 2027-04-15 |
| NCT07312292Niek WijnenRadioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT) | 2027-05-01 |
| NCT07717437Maastricht University Medical CenterDRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection. | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 53 studies in Carcinoma, Hepatocellular with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The endpoint of this study is to develop and validate algorithms, using artificial intelligence and machine learning, to optimize patient selection, treatment planning, treatment evaluation and outcome prediction in patients undergoing thermal ablation of a malignant liver tumor. The long-term objective is to establish thermal ablation as the treatment of choice for the vast majority of patients with a primary or secondary liver tumor by development of an accessible workflow that can be widely implemented in different centers performing thermal ablation. Over a time span of at least four years, data will be collected prospectively, encompassing patient information, tumor characteristics, and treatment details. Additionally, pre-, intra-, and post-procedural imaging will be systematically gathered.
This study is part of the IMAGIO (Imaging and advanced guidance for workflow optimization in interventional oncology) project. This project aims to leverage Interventional Oncology in the clinical setting to improve cancer survival outcomes, through minimally invasive, efficient and affordable care pathways for three disease states; liver cancer, lung cancer and sarcoma. In IMAGIO, top innovators in MedTech and Pharma and expert academic clinical centers will mature the next-generation interventional oncology imaging across the full spectrum, from pre-clinical developments to impact validation in clinical trials.
The objective of this study, A-IMAGIO, is to develop a standardized, accessible, low-complex, end-to-end solution for patient selection, treatment planning, needle guidance and treatment evaluation for thermal liver ablation.
One of the objectives is to integrate AI in the clinical workflow as a tool to assist operators in decision making throughout the entire process based on quantitative assessment. AI data analytics will be developed to guide decision making for personalized treatment together with algorithms that allow optimized treatment planning and automated quantitative treatment evaluation. Also, a computational model will be developed with input from radiomics and clinical data to identify patients at risk of recurrence after thermal ablation. The aim of the A-IMAGIO project is to conduct a large European observational cohort study and collect clinical and image data of patients treated with thermal ablation for liver tumors in order to develop and validate these AI algorithms. The database will be built by merging data from retrospective data and previous prospective clinical trials on thermal ablation of liver tumors. Further data will be collected through a prospective, multicenter, observational study. The long-term objective is to establish thermal ablation as the first line therapy for patients with both primary and secondary liver tumors. Therefore, we aim to develop a low-complexity-high-precision, accessible workflow that can be widely implemented in different centers performing thermal ablation.
3,656 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,068 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 200 across 853 observational studies indexed under Carcinoma, Hepatocellular.
Browse Carcinoma, Hepatocellular studies →Leiden University Medical Center is the lead sponsor of 334 studies on the registry; 110 are open to participants now.
Compared within Carcinoma, Hepatocellular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Liver Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
All patients diagnosed with one or more primary or secondary liver malignancy who are candidates for thermal liver ablation as discussed in a multidisciplinary tumour board.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Efficacy as assessed by local recurrence
Time frame: Throughout the entire four-year study period
Efficacy as assessed by time-to-recurrence
Time frame: Throughout the entire four-year study period
Efficacy as assessed by disease-free-survival
Time frame: Throughout the entire four-year study period
Efficacy as assessed by overall survival
Time frame: Throughout the entire four-year study period
Safety as assessed by complications according to CTCAE v6.0.
Treatment related adverse events are defined as grade 3-4 adverse events and serious
Time frame: Throughout the entire four-year study period
Plan to share: Undecided
Started Jan 2024 (actual). Primary completion is estimated for Dec 2027, 47 months after the start.
Of 303 non-industry observational studies under Carcinoma, Hepatocellular, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 114. This study's planned 47 months is below that.
Counting every sponsor, half of 352 studies reached it within 51 months; a quarter within 32 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leiden University Medical Center →